On Monday, the U.S. Food and Drug Administration (FDA) approved Pixclara (floretyrosine F18), an amino acid positron emission tomography (PET) imaging agent created by Telix Pharmaceuticals Limited (NASDAQ:TLX) to diagnose brain cancer.
Key Indications And Regulatory Milestone
Pixclara serves as a radioactive diagnostic drug administered intravenously for PET imaging to differentiate recurrent or progressive glioma (a type of brain tumor) from treatment-related change.
Healthcare professionals can utilize the imaging drug in conjunction with other diagnostic evaluations for adult patients, as well as pediatric patients who are one month of age and older.
Following this regulatory decision, Pixclara becomes the only FDA-approved radiopharmaceutical imaging drug designated specifically for glioma.
While international clinical practice guidelines, such as the NCCN Guidelines, currently recommend floretyrosine F 18 PET imaging for managing gliomas, healthcare providers in the United States previously operated without access to an FDA-approved product.
Mechanism Of Action
The diagnostic formulation incorporates a small-molecule targeting compound labeled with fluorine-18, which is a diagnostic radioisotope.
After medical staff inject the drug into a patient’s bloodstream, Pixclara specifically targets membrane transport proteins known as L-type amino acid transporters 1 and 2, or LAT1 and LAT2.
Once the compound binds to these specific transporters, energy emissions originating from the radioisotope can be picked up and detected by a standard PET scanner.
Ongoing Trials And Potential Expansion
Beyond its approved use for glioma imaging, the diagnostic compound—referred to internally as TLX101-Px—is currently undergoing further evaluation in a Phase 3 registrational study.
Researchers are exploring a potential indication expansion that could allow the product to assist in diagnosing brain metastases in the future.
William Blair wrote, “Although a relatively modest contribution to sales, we are encouraged that the approval provides a means for Telix to diversify its revenue streams beyond the PSMA PET franchise.”
TLX Price Action: Telix Pharmaceuticals shares were up 7.44% to $12.13 at the time of publication on Monday. The stock is approaching its 52-week high of $12.48, according to Benzinga Pro data.
Image via Shutterstock